LIQUIDIA CORPORATION

LQDA ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-68.9M $-128.3M $-78.5M $-41.0M $-34.6M $-59.8M $-47.6M
Depreciation & Amortization $1.5M $2.2M $2.2M $3.6M $5.6M $3.1M $2.6M
Depreciation
Amortization $200.0K $300.0K $300.0K $700.0K $1.1M
Stock-Based Compensation $29.5M $18.8M $10.1M $9.3M $6.7M $4.0M $3.4M
Net Cash from Operating Activities $-35.7M $-93.4M $-41.6M $-28.6M $-34.0M $-54.1M $-48.3M
Investing Activities
Capital Expenditures $4.3M $4.9M $1.3M $592.0K $107.0K $752.1K $1.9M
Business Acquisitions
Net Cash from Investing Activities $-6.3M $-8.4M $-11.3M $-587.0K $-107.0K $247.9K $-1.9M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $59.7M $194.7M $43.2M $65.0M $26.3M $63.4M $66.4M
Net Change in Cash $17.7M $92.8M $-9.6M $35.8M $-7.8M $9.5M $16.3M
Free Cash Flow $-40.0M $-98.4M $-42.9M $-29.2M $-34.1M $-54.9M $-50.1M